Scientists Turn Plastic Waste Into Parkinson’s Drug In Stunning Medical Breakthrough

by Aaron Leong — Monday, March 30, 2026, 01:18 PM EDT

Scientists at the University of Edinburgh have successfully transformed common plastic waste into a high-value precursor for Parkinson’s disease medication. Using engineered E. coli bacteria, the team converted polyethylene terephthalate (PET) into adipic acid, which was then further synthesized into a vital drug component, proving that the circular economy can sometimes extend even into the world of neurobiology.

The process begins with the breakdown of PET, the ubiquitous plastic found in single-use water bottles and food packaging. PET recycling currently is a mechanical process that results in lower-quality plastic, eventually leading to the landfill. However, the University of Edinburgh team, led by Professor Stephen Wallace, pioneered a biological approach. They utilized a chemical-biological method, first using chemical catalysts to break down the plastic into its base monomers, specifically terephthalic acid. From there, a genetically modified strain of E. coli is introduced, which is programmed to consume the terephthalic acid and, through a series of enzymatic reactions, convert it into muconic acid and subsequently adipic acid.

Professor Stephen Wallace

Adipic acid is a versatile industrial building block, but the real breakthrough lies in its further conversion into vanillin and other catechol-derived substances. In this specific study (published in the Nature journal), the researchers focused on the synthesis of levodopa (L-DOPA), the primary medication used to manage the motor symptoms of Parkinson's disease. L-DOPA works by increasing dopamine levels in the brain, and its production usually relies on petroleum-derived precursors. By sourcing these precursors from plastic waste instead of fossil fuels, the study demonstrates a dual-benefit system: reducing non-biodegradable waste while lowering the carbon footprint of pharmaceutical manufacturing.

This breakthrough truly shows off what synthetic biology can achieve. The researchers optimized the E. coli metabolic pathways so that the bacteria could handle the chemical toxicity of the plastic derivatives while maintaining a solid output of the desired compound. This upcycling is definitely more valuable than recycling, which in this case proves that even if a discarded plastic bottle has almost zero value, the medicinal compounds derived from it are worth thousands of dollars per kilogram.

As the global population ages, the prevalence of Parkinson’s disease is expected to rise, increasing the demand for affordable L-DOPA. Simultaneously, the world is grappling with over 350 million tonnes of plastic waste produced annually. Integrating these two crises into a single solution couldn't have arrived at a better time amidst a critical juncture for health and environmental policy.

Image credits: Edinburgh Innovations